Every 10-Q that Drugs Made In America Acquisition Corp. (DMAA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DMAA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMAA filings page.
Drugs Made In America Acquisition Corp., a Cayman Islands SPAC, reported June 30, 2026 assets of $146.9 million, including $146.8 million of cash and investments in its Trust Account and $20,280 of operating cash. Ordinary shares subject to possible redemption totaled 13,559,770 with a redemption value of $145.2 million.
During the April 27, 2026 extension vote, holders of 9,440,230 shares redeemed for $99.3 million (about $10.52 per share), significantly reducing the Trust balance. An investor deposited $600,000 via Extension Advance Notes by June 30, 2026 to extend the combination deadline, with an additional $300,000 deposited on July 27, 2026. Net income was $3.7 million for the six months, driven by $4.0 million of interest on Trust investments and low operating costs. The company entered into a Definitive Merger Agreement with PAGC on April 29, 2026. Management discloses a working capital deficit of $2.9 million and states that the mandatory liquidation date and funding needs raise substantial doubt about its ability to continue as a going concern absent completion of a Business Combination within the extended period.
Drugs Made In America Acquisition Corp. reported Q1 2026 net income of $1.97 million, driven by $2.11 million of interest on its $242.0 million trust account and modest general and administrative costs of $143,301.
The SPAC remains pre‑revenue, with cash of $14,887 and a working capital deficit of $477,282, and its auditors highlight substantial doubt about its ability to continue as a going concern without completing a business combination. In April 2026, shareholders approved an extension of the combination deadline to as late as April 29, 2027, with redemptions of 9,440,230 shares for about $99.3 million, leaving 24,276,913 ordinary shares outstanding. The company also signed an interim $100,000 convertible note and a definitive merger agreement with Power Analytics Global Corp., positioning that business as the intended operating company after the de‑SPAC transaction.
Drugs Made In America Acquisition Corp. (DMAA) reported net income of $2.18 million for the quarter and $5.73 million for the nine months ended September 30, 2025, driven almost entirely by $6.45 million of interest earned on the cash and investments held in its trust account. Operating expenses remain modest, with general and administrative costs of $263,703 for the quarter and $726,547 year-to-date as the SPAC continues to search for a pharmaceutical-sector business combination.
The company’s balance sheet shows $237.6 million of cash and investments in the trust account, backing 23,000,000 ordinary shares subject to redemption at $10.33 per share, while cash outside the trust is only $717 and working capital shows a deficit of $428,415. Management discloses that the mandatory liquidation deadline—15 months after the IPO closing, or up to 21 months if extensions are funded—raises substantial doubt about the company’s ability to continue as a going concern if no business combination is completed within this “Combination Period.”